This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Data Published Identify The Folate Receptor As A Potential Biomarker For Targeted Therapies In A Majority Of Lung Cancers

- Results Show 72 Percent of Adenocarcinomas and 51 Percent of Squamous Cell Carcinoma of the Lung Express Folate Receptor -

- Data Published in Archives of Pathology & Laboratory Medicine -

WEST LAFAYETTE, Ind., Oct. 12, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced the publication of data showing that 72 percent of adenocarcinomas and 51 percent of squamous cell carcinomas of the lung were positive for the folate receptor (FR). Currently validated targeted therapies are effective in only a small minority of lung cancers so the FR may be an important molecular target for future lung cancer therapies. The data are published online in the journal Archives of Pathology & Laboratory Medicine .

"Lung cancer remains the number one cause of cancer death in the world, however only a limited percentage of lung cancers are candidates for targeted therapies based on EGFR mutation and ALK fusion genes, demonstrating the need for new targeted therapeutics," said Philip Low, Ph.D., chief scientific officer of Endocyte and co-author of the publication. "The high level of FR expression in lung cancer suggests that a large percentage of lung cancer patients might benefit from a FR-targeted therapy. Our use of the companion diagnostic imaging agent, etarfolatide, may allow us to select patients based on the expression of the FR immediately prior to therapy."

In the study, high-density tissue microarrays were immunostained for the FR and the immunopositivity was scored. The tissue microarrays constructed from archival formalin-fixed, paraffin-embedded resection specimens from 117 patients with primary adenocarcinomas and 71 patients with squamous cell carcinomas of the lung, either stage I or stage II.

"Our etarfolatide companion diagnostic imaging research has also demonstrated that the FR is commonly present in adenocarcinomas, approximately 80 percent of patients have tested positive for the FR," said Binh Nguyen M.D., Ph.D., vice president of clinical affairs at Endocyte. "What is particularly exciting about this new research is the presence of the FR in squamous cell carcinomas where there is an even greater need for effective folate-targeted therapies."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,985.61 +78.99 0.47%
S&P 500 1,972.83 +9.12 0.46%
NASDAQ 4,419.0340 +27.5710 0.63%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs